In the effort to contain the COVID-19 pandemic serological testing to detect SARS-CoV-2 specific antibodies will be important in disease and community management.
Gentian is developing a turbidimetric SARS-CoV-2 Total Antibody Immunoassay in collaboration with the University in Tromsø (UiT). The quantitative antibody test captures the full immune response detecting antibodies targeting the S1 subunit with high sensitivity and specificity and will be calibrated against the international WHO standard.
Gentian will bring SARS-CoV-2 serology testing to automated, open-access clinical chemistry platforms, increasing both the testing capacity (up to 2000 tests/hour) and the laboratory efficiency. Since the Gentian assay is platform agnostic it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost. The test will follow a standard testing protocol utilising existing logistic structure, from the routine blood test at the GP office to the clinical chemistry platforms with an assay time of only 10 minutes.
The Gentian assay will provide the tool to achieve documented protection for individuals and society. It allows the tracking of the total antibody response targeting the S1 subunit, to assess the level of protection. It will provide a powerful high-throughput test for community management of COVID-19 through long-term monitoring of natural and vaccine-related immune response.
The Gentian SARS-CoV-2 Total Antibody Immunoassay is calibrated against the WHO International Standard for anti-SARS-CoV-2 antibody, enabling harmonisation between results across laboratories and serological assays. The standardisation allows scientist, health care workers and laboratories to directly compare results, minimising variation and calibration correction.
Capture Total Ab Response
First WHO International Standard
Let us know if you want more information about the assay or want to validate the assay in your laboratory at the time of launch.
Please send us an email to email@example.com or fill out the form to the right. Our Product Manager for SARS-CoV-2 Total Antibody Immunoassay will get in touch.